- Cancer Biology & Biomarkers
- Chromatography & Mass Spectrometry
- Contract Research, Clinical Trials and Outsourcing
- Drug Discovery
- Drug Targets
- Flow Cytometry
- Informatics & Lab Automation
- Ingredients, Excipients and Dosages
- Microbiology & RMMs
- NIR, PAT & QbD
- Raman Spectroscopy
- Screening, Assays & High-Content Analysis
- Thermal Processing
- Events & Workshops
Peptide vaccines and immuno-oncology products hold promise in glioblastoma
15 March 2016 • Author: Victoria White
The termination of Celldex’s Phase III trial assessing Rintega in newly-diagnosed glioblastoma patients, represents a blow to the treatment space as hopes for improved therapies turn instead to Opdivo and drugs combining peptide vaccines with immuno-oncology products, according to analysts with research and consulting firm GlobalData.
In a press release, Celldex stated that the trial was terminated because “Rintega has performed consistently with prior Phase II studies but the control arm has significantly outperformed expectations.”
Dan Roberts, Ph.D., GlobalData’s Senior Analyst covering Oncology and Haematology, explains: “The fact that this study involved a control arm which outperformed historical controls was not unexpected, as patients who were enrolled in this trial underwent total resection and had no evidence of a progressive disease.”
Indeed, as stated in GlobalData’s glioblastoma report from December 2015, “comparison to historical values must be interpreted with caution, as these patients typically have higher survival than the general glioblastoma population.”
Immunotherapy agents “hold great promise”
Maxime Bourgognon, PharmD, GlobalData’s Analyst covering Oncology and Haematology, says that despite Rintega’s disappointments, there are reasons for glioblastoma patients to be optimistic, as immunotherapy agents hold great promise for those faced with high unmet needs and extremely poor survival.
Bourgognon explains: “There are several late-stage vaccines being evaluated for glioblastoma patients, with ImmunoCellular Therapeutics’ ICT-107 holding the highest probability of success.
“It is also anticipated that the upcoming launch of Bristol-Myers Squibb’s PD-1 inhibitor, Opdivo, in both the newly-diagnosed and recurrent settings, will change glioblastoma’s treatment algorithm by improving patient survival.”
GlobalData believes that while peptide vaccines are currently underdeveloped, they hold promise going forward, particularly if they are made up of potential synergistic combinations with active immuno-oncology products which specifically target the immune system, such as checkpoint inhibitors.
Roberts concludes: “Combining peptide vaccines with active immuno-oncology products is scientifically and commercially promising, as these combinations will be able to differentiate themselves in an increasingly crowded glioblastoma market.”
ABB Analytical Measurement ACD/Labs ADInstruments Ltd Advanced Analytical Technologies GmbH Analytik Jena AG Astell Scientific Ltd Bachem AG Bibby Scientific Limited Bio-Rad Laboratories BioNavis Ltd Biopharma Group Black Swan Analysis Limited Charles Ischi AG | Kraemer Elektronik Cherwell Laboratories CI Precision Cobalt Light Systems Coulter Partners CPC Biotech srl Dassault Systèmes BIOVIA DiscoverX Edinburgh Instruments Enterprise System Partners (ESP) EUROGENTEC F.P.S. Food and Pharma Systems Srl IDBS JEOL Europe L.B. Bohle Maschinen + Verfahren GmbH Lab M Ltd. LabWare Linkam Scientific Instruments Limited Molins Technologies Multicore Dynamics Ltd Nanosurf New England Biolabs, Inc. Panasonic Biomedical Sales Europe B.V. PerkinElmer Inc ReAgent Russell Finex Limited Source BioScience Takara Clontech Tornado Spectral Systems Tuttnauer Watson-Marlow Fluid Technology Group Wickham Laboratories Limited Xylem Analytics YMC Europe GmbH Yusen Logistics